Codon-Optimized CFTR mRNA Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering CFTR gene therapy to treat cystic fibrosis face challenges such as immune responses and the inability of non-viral DNA vectors to import DNA into the nucleus, where transcription occurs, limiting effective expression of the CFTR protein in lung tissues.
Innovation Solution
The development of codon-optimized mRNA encoding the CFTR protein, synthesized in vitro using SP6 RNA polymerase, which is substantially free of secondary polynucleotide species and can be produced in large batches, facilitating efficient and stable expression of the CFTR protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral vectors comprising CFTR DNA are used for gene delivery, then CFTR expression can be achieved, but immune responses are triggered and CF symptoms persist
Solution Approach 1:
The invention extracts only the essential coding sequence of CFTR and delivers it as mRNA rather than whole DNA, eliminating the need for nuclear import and reducing immune recognition of viral components while maintaining therapeutic efficacy
Solution Approach 2:
Instead of delivering DNA that requires nuclear import, the invention creates an mRNA copy of the CFTR coding sequence that can be directly translated in the cytoplasm, bypassing nuclear barriers and reducing immunogenicity
2Object-affected harmful factors
If non-viral DNA vectors are used for CFTR delivery, then immune responses are avoided, but the machinery of the nuclear pore complex does not ordinarily import DNA into the nucleus
Solution Approach 1:
The invention creates an mRNA copy of the CFTR gene that bypasses the need for nuclear import entirely, as mRNA translation occurs in the cytoplasm. This resolves the contradiction by eliminating both the immune response issue and the nuclear import barrier simultaneously
Solution Approach 2:
The invention uses mRNA as an intermediary between the CFTR gene and the protein production machinery, allowing genetic information transfer without requiring DNA to cross the nuclear membrane
3Productivity
If in vitro transcription is performed to produce mRNA, then full-length mRNA can be synthesized, but secondary polynucleotide species may be produced
Solution Approach 1:
The invention optimizes transcription parameters including template design with specific promoter sequences, reaction temperature, and enzyme selection to maximize full-length mRNA production while minimizing secondary species formation
Solution Approach 2:
The invention incorporates purification steps immediately after transcription to remove secondary polynucleotide species before the mRNA is used, ensuring high purity while maintaining high yield through efficient recovery protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables high-yield, full-length mRNA production that minimizes immune responses and effectively expresses the CFTR protein, potentially addressing the limitations of existing CFTR gene therapy delivery methods by ensuring substantial purity and stability of the mRNA.
Implementation Method 1
in vitro transcription of the codon optimized CFTR mRNA from a DNA template, wherein the codon optimized CFTR mRNA comprises a polynucleotide sequence identical to SEQ ID NO: 1
Data Source
Figure 1
AI summary
The present invention provides, among other things, improved methods and pharmaceutical compositions for treating cystic fibrosis based on codon optimized mRNA encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein.